Cristina Gonçalves

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 375 citations · Full text

Hematological Malignancy, Medicine, Hematology +6

Consistent Fusion of ZNF198 to the Fibroblast Growth Factor Receptor-1 in the t(8;13)(p11;q12) Myeloproliferative Syndrome

Andreas Reiter, Jastinder Sohal, Shashikant Kulkarni et al. · Blood · 1998 · 169 citations

Genotype correlates with the natural history of severe bile salt export pump deficiency

Daan van Wessel, Richard J. Thompson, Emmanuel Gonzalès et al. · Journal of Hepatology · 2020 · 114 citations · Full text

Quantitative Genetics, Allergy, Biliary Tract +7

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

Mohamad Mohty, Evangelos Terpos, María‐Victoria Mateos et al. · Clinical Lymphoma Myeloma & Leukemia · 2018 · 89 citations · Full text

Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial

Cyrille Hulin, Andrew R. Belch, Chaim Shustik et al. · Journal of Clinical Oncology · 2016 · 81 citations

Progression-free Survival, Immunology, Pharmacotherapy +20